VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Recurrent Endometrial Carcinoma
Interventions
BIOLOGICAL

ziv-aflibercept

Trial Locations (67)

11794

Stony Brook University Medical Center, Stony Brook

19001

Abington Memorial Hospital, Abington

20010

Washington Hospital Center, Washington D.C.

21237

Franklin Square Hospital Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

24016

Carilion Clinic Gynecological Oncology, Roanoke

27157

Wake Forest University Health Sciences, Winston-Salem

27834

Gynecologic Oncology Network, Greenville

28204

Novant Health Presbyterian Medical Center, Charlotte

31403

Memorial Health University Medical Center, Savannah

32803

Florida Hospital, Orlando

33458

Jupiter Medical Center, Jupiter

43214

Riverside Methodist Hospital, Columbus

43222

Mount Carmel Health Center West, Columbus

44060

Lake University Ireland Cancer Center, Mentor

44106

Case Western Reserve University, Cleveland

44109

MetroHealth Medical Center, Cleveland

44111

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44195

Cleveland Clinic Foundation, Cleveland

45409

Miami Valley Hospital, Dayton

46260

Saint Vincent Hospital and Health Services, Indianapolis

49431

Green Bay Oncology - Escanaba, Escanaba

49801

Green Bay Oncology - Iron Mountain, Iron Mountain

52242

University of Iowa Hospitals and Clinics, Iowa City

53792

University of Wisconsin Hospital and Clinics, Madison

54154

Green Bay Oncology - Oconto Falls, Oconto Falls

54235

Green Bay Oncology - Sturgeon Bay, Sturgeon Bay

54301

Saint Vincent Hospital, Green Bay

54303

Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay

Saint Mary's Hospital, Green Bay

60611

Northwestern University, Chicago

60612

University of Illinois, Chicago

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

64057

Centerpoint Medical Center LLC, Independence

64068

Liberty Hospital, Liberty

64108

Truman Medical Center, Kansas City

64111

Saint Luke's Cancer Institute, Kansas City

Saint Luke's Hospital of Kansas City, Kansas City

64114

Radiation Oncology Practice Corporation South, Kansas City

Saint Joseph Health Center, Kansas City

64116

North Kansas City Hospital, Kansas City

64132

Research Medical Center, Kansas City

64154

Radiation Oncology Practice Corporation - North, Kansas City

64506

Heartland Regional Medical Center, Saint Joseph

66044

Lawrence Memorial Hospital, Lawrence

66061

Radiation Oncology Center of Olathe, Olathe

66112

Providence Medical Center, Kansas City

66204

Shawnee Mission Medical Center, Shawnee Mission

66209

Menorah Medical Center, Overland Park

66210

Radiation Oncology Practice Corporation Southwest, Overland Park

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74104

Cancer Care Associates-Midtown, Tulsa

74146

Tulsa Cancer Institute, Tulsa

77030

M D Anderson Cancer Center, Houston

87106

Southwest Gynecologic Oncology Associates Inc, Albuquerque

University of New Mexico Cancer Center, Albuquerque

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

98195

University of Washington Medical Center, Seattle

98405

Northwest Medical Specialties PLLC, Tacoma

06102

Hartford Hospital, Hartford

06050

The Hospital of Central Connecticut, New Britain

02114

Massachusetts General Hospital Cancer Center, Boston

08103

Cooper Hospital University Medical Center, Camden

02905

Women and Infants Hospital, Providence

54301-3526

Green Bay Oncology at Saint Vincent Hospital, Green Bay

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00462826 - VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer | Biotech Hunter | Biotech Hunter